Bookbot

Recombinant monoclonal antibody trastuzumab for the treatment of metastatic breast cancer with tumors overexpressing the HER2-neu proto-oncogene

More about the book

The objectives of the review were to evaluate the clinical effectiveness and cost-effectiveness of trastuzumab in the management of advanced breast cancer. Only randomised controlled trials of trastuzumab alone, or in combination with other agents, versus systemic therapy without trastuzumab, were initially considered in the assessment of clinical effectiveness. The assessment of cost effectiveness includes only full economic evaluations. -- abstract.

Book purchase

Recombinant monoclonal antibody trastuzumab for the treatment of metastatic breast cancer with tumors overexpressing the HER2-neu proto-oncogene, Marcus Oehlrich

Language
Released
2003
product-detail.submit-box.info.binding
(Paperback)
We’ll email you as soon as we track it down.

Payment methods

No one has rated yet.Add rating